Medicago, a biotechnology company, has completed initial studies towards the development of a new VLP vaccine candidate for rabies.

People with high cholesterol are at risk of heart attack and stroke because atherosclerotic plaques within their arteries can rupture triggering the formation of a blood clot called an occlusive thrombus that cuts off the blood supply to their heart or brain.

A new study has discovered how hepatitis C virus survives in the liver – helping medical scientists understand why a new antiviral drug appears to be effective against the virus.

Sanofi and its subsidiary Genzyme has announced new data from the TEriflunomide multiple sclerosis oral (TEMSO) phase III trial showing once-daily oral teriflunomide significantly reduced annualized rates of relapses leading to hospitalization. New data also confirmed the safety profile and efficacy of teriflunomide over a six-year period after the initial randomization.

CRANE ChemPharma Flow Solutions announced the launch of its new BioPharm applications module, an addition to its existing www.cranechempharma.com website.  The new interactive module can be also accessed directly at www.cranebiopharm.com, allowing an easier and faster link to CRANE [Saunders®, ResistoPure®, and DEPA®] flow solutions for global BioPharm and Pharmaceutical markets.  

French scientists have developed a novel hepatitis C vaccine that may offer the first effective way to prevent an infection that can cause chronic liver disease and cancer. There is currently no available vaccine for hepatitis C, though some companies are developing so-called "therapeutic vaccines," which are designed to help patients who are already infected.

Oracle Health Sciences announced the availability of Oracle Health Sciences InForm Global Trial Management (GTM) 5.5, which includes powerful new functionality to help trial sponsors and clinical research organizations (CROs) improve clinical trial efficiency and increase the productivity of study managers, monitors, and clinical data managers.

People living in an area of the southeastern United States known as the "Stroke Belt" are also at greater risk for cognitive decline, or reduced brain function, than those living in other areas, new research suggests.

Combining omega-3 fatty acids with blood-thinning drugs may reduce the risk of heart attacks in patients who've had stents placed in their coronary arteries, a new European study suggests.

Novozymes Biopharma, part of Novozymes A/S, the world leader in bioinnovation, today unveiled its enhanced next-generation albumin technology, which was developed in collaboration with the University of Oslo, Norway, one of the world’s leading institutions in the research of albumin variants and the neonatal Fc receptor (FcRn). Built on Novozymes’ original albufuse platform, the proprietary Albufuse Flex technology has been designed to enable users to adapt and control the pharmacokinetics of their target protein or peptide with retained efficacy, ensuring flexibility and optimal use.